Spero Therapeutics Announces Second Quarter 2025 Operating Results and Provides a Business Update
CAMBRIDGE, Mass., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for ...
What is the market's perception of the long‑term growth prospects for SPRO based on the Q2 results and business update?
Did the company announce any share repurchases, secondary offerings, or other capital structure actions that could affect liquidity or dilution?
What potential catalysts or risk factors were highlighted that could drive short‑term volatility in the stock price?
26 days ago